AQST — Aquestive Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1398733 ·
Last close
$4.68
Market Cap
$587.39M
52W High
$7.55
52W Low
$2.93
ADV30
2,884,510
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 13,819,000 | 9,802,000 | -8,223,000 | -22,864,000 | 132,104,000 | 98,490,000 | 188,690,000 |
| Mar 2026 | 14,446,000 | 10,977,000 | -4,204,000 | -8,057,000 | 141,125,000 | 110,734,000 | 175,179,000 |
| Dec 2025 | 13,015,000 | 7,179,000 | -28,839,000 | -31,860,000 | 160,425,000 | 121,169,000 | 194,087,000 |
| Sep 2025 | 12,807,000 | 8,301,000 | -11,479,000 | -15,446,000 | 163,559,000 | 129,063,000 | 167,668,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,838,000
Investing CF
$-479,000
Financing CF
$86,394,000
CapEx
$-479,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.61
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-455,055,000
Inventory
$8,066,000
Receivables
$6,867,000
ST Investments
—
EBIT TTM
$-52,153,000
Pretax Income TTM
$-68,911,000
Interest Exp TTM
$16,758,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$54,087,000
EBITDA
$-52,201,000
Free Cash Flow
$-26,891,876
Enterprise Value
$560,486,656
Total Cash
$98,490,000
Total Debt
$59,031,000
Shares Out
125,511,648
Trailing EPS
$-0.66
Book Value
$-0.45
ROE
—
ROA
-29.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,545,000 | -71,051,000 | -83,784,000 | 160,425,000 | 194,087,000 | -33,662,000 | -52,432,000 |
| Dec 2024 | 57,561,000 | -30,771,000 | -44,137,000 | 101,424,000 | 161,580,000 | -60,156,000 | -35,759,000 |
| Dec 2023 | 50,583,000 | -15,102,000 | -7,870,000 | 57,418,000 | 163,905,000 | -106,487,000 | -6,380,000 |
| Dec 2022 | 47,680,000 | -42,066,000 | -54,410,000 | 57,070,000 | 175,624,000 | -118,554,000 | -9,819,000 |
TTM Snapshot
Revenues TTM
$22,262,000
NetIncome TTM
$-34,439,000
OpCashFlow TTM
$0
Assets (Latest)
$160,425,000
Forward EPS
$-0.57
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $4.61 · call oi: 12,915 · put oi: 1,444
Expected Move to 2026-10-16:
±$0.62
(13.56%) —
implied range
$3.99 –
$5.24
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | $588.33M | $2.70 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $590.58M | $7.30 | — |
| ALT | Altimmune, Inc. | $595.22M | $3.06 | — |
| VREOF | Vireo Growth Inc. | $572.19M | $11.26 | — |
| MNPR | Monopar Therapeutics | $572.11M | $85.24 | — |
News headlines (Yahoo Finance, 1h cache)
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
2026-09-17 11:00 · Yahoo
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
2026-09-08 02:07 · Yahoo
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-01 11:00 · Yahoo
Aquestive (AQST) Q2 2026 Earnings Call Transcript
2026-08-18 23:31 · Yahoo
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
2026-08-12 23:04 · Yahoo
Aquestive Therapeutics Q2 Earnings Call Highlights
2026-08-12 14:05 · Yahoo
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 21:25 · Yahoo
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:01 · Yahoo
Aquestive Therapeutics shares jump after encouraging Anaphylm study results
2026-08-10 14:24 · Yahoo
Aquestive Therapeutics' Potential Allergy Film Shows Improvements in Human Factors Study
2026-08-10 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.